MyMD Pharmaceuticals Enrolls First Client in Stage 2 Professional Trial of MYMD-1 as a Treatment for Delaying Aging and also Increasing Healthy And Balanced Life-span

MyMD Pharmaceuticals, Inc. MYMD stock price (” MyMD” or “the Firm”), a scientific stage pharmaceutical company devoted to prolonging healthy and balanced lifespan, today revealed that the initial client has been registered in the Firm’s Stage 2 clinical test of lead candidate MYMD-1, a dental immune regulator medication, as a treatment for delaying aging and also increasing healthy lifespan.

The main endpoint for the Stage 2 double-blind, placebo-controlled scientific trial is to achieve a decrease in the circulating levels of (TNF-α), growth death aspect receptor I (TNFRI) as well as IL-6. TNF-α and also IL-6 are the proteins in the body that create inflammation and aid turn on the process of aging. The second measures of the test will certainly be the safety, tolerability, as well as pharmacokinetics in this population of people.

” In a Stage 1 professional trial of MYMD-1, we showed the medication’s statistically significant effectiveness in reducing degrees of TNF-α, a principal in creating pathological aging, in the blood. The FDA has actually accepted TNF-α decrease as the key endpoint for our Stage 2 research, which our team believe positions us well for a successful Phase 2 result,” said Chris Chapman, M.D., Head Of State, Director as well as Principal Medical Officer of MyMD. “The initiation of patient registration in this research developments our goal to slow the aging process, avoid loss of muscle mass tissue in aging, limit frailty, and also extend healthy life expectancy.”

MyMD has actually specified that there are no FDA-approved drugs for treating aging disorders and also prolonging healthy and balanced life-span humans, a market anticipated to be at least $600 billion by 20251 according to a significant financial investment financial institution. TNF-α blockers are the most recommended drugs by revenue, an international market of around $40 billion per year,2 and also, according to Nature Aging journal,3 a downturn in maturing that would certainly enhance life expectancy by one year is worth $38 trillion as well as by 10 years is worth $367 trillion.

In addition to aging, MYMD-1’s distinctive activity in managing the body immune system and also dealing with chronic swelling is being developed for the treatment of autoimmune disease, including rheumatoid joint inflammation (RA), several sclerosis (MS), diabetes mellitus, and also inflammatory digestive tract condition.

” We mean to begin writing protocols for a Stage 2 pilot research of MYMD-1 for rheumatoid arthritis early this year,” Dr. Chapman noted. “The rising occurrence of rheumatoid joint inflammation as well as other autoimmune as well as inflammatory conditions are driving demand for TNF inhibitors like MYMD-1, and our company believe our by mouth administered medication with extremely reduced poisoning would be disruptive to the $60 billion market for RA if authorized by the FDA for this indication.”

Rheumatoid joint inflammation affects around 40 million people around the world.4.

Regarding MYMD-1.

Initially created for autoimmune illness, MYMD-1’s primary function is to reduce the aging procedure, protect against sarcopenia as well as frailty, as well as extend healthy and balanced life-span. Due to the fact that it can go across the blood-brain obstacle as well as gain access to the main nerve system (CNS), MYMD-1 is additionally positioned to be a possible treatment for brain-related problems. Its system of action and efficiency in diseases consisting of multiple sclerosis (MS) and also thyroiditis have actually been examined through partnerships with numerous academic establishments. MYMD-1 is likewise revealing promise in pre-clinical researches as a potential treatment for article- COVID-19 difficulties and as an anti-fibrotic as well as anti-proliferation healing.

MYMD-1 has shown efficiency in pre-clinical research studies in regulating the immune system by performing as a selective inhibitor of lump necrosis factor-alpha (TNF-α), a motorist of persistent swelling. Unlike various other therapies, MYMD-1 has actually been displayed in these pre-clinical studies to precisely block TNF-α when it becomes overactivated in autoimmune diseases and also cytokine storms, yet not block it from doing its typical job of being an initial -responder to any regular kind of modest infection. MYMD-1’s ease of dental application is one more differentiator contrasted to currently offered TNF-α blockers, all of which call for delivery by shot or infusion. No authorized TNF prevention has actually ever been dosed orally. In addition, the drug is not immunosuppressive as well as has actually not been shown to create the major side effects typical with traditional treatments that deal with swelling.

Regarding MyMD Pharmaceuticals, Inc

. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a scientific phase pharmaceutical company dedicated to prolonging healthy life expectancy, is concentrated on establishing 2 unique healing platforms that deal with the root causes of condition as opposed to just dealing with the symptoms. MYMD-1 is a medicine platform based on a clinical phase tiny particle that regulates the body immune system to manage TNF-α, which drives chronic inflammation, and also other pro-inflammatory cell signaling cytokines. MYMD-1 is being created to delay aging, increase longevity, as well as deal with autoimmune illness and also COVID-19- connected anxiety. The Company’s second medication platform, Supera-CBD, is being created to deal with chronic pain, dependency and epilepsy. Supera-CBD is a novel artificial derivative of cannabidiol (CBD) and also is being established to address and improve upon the quickly expanding CBD market, which includes both FDA authorized medicines and also CBD products not presently managed as drugs. For more information, go to www.mymd.com.